ASH Hematology-Focused Fellowship Training Program (HFFTP)
The Yale School of Medicine has a rich history of innovations in classical hematology. For 50 years, Yale has been home to numerous landmark discoveries in hemoglobin and red cell disorders, hematopoiesis, platelet biology, and, more recently, COVID-19.
The Yale HFFTP draws upon the diverse clinical and scholarly strengths of Yale and its numerous interdisciplinary programs to provide an entirely novel curriculum with robust clinical training and unparalleled research opportunities in all aspects of classical hematology. The fellowship provides broad exposure to a wealth of collaborative research programs, interdisciplinary pathways, and opportunities for advanced degree training.
Fellows in the Yale HFFTP receive rigorous clinical training across a vast spectrum of hematologic diseases, including hemophilia, hemostatic and thrombotic disorders, sickle cell disease, red cell disorders, vascular malformations, hematologic malignancies, and rare diseases. A longitudinal curriculum in research methodology, numerous teaching conferences, and rotations in transfusion and laboratory medicine, molecular diagnostics, and genetics complement the clinical training. The Yale HFFTP aims to mentor classical hematology-focused fellows who will lead the field in both traditional and innovative scholarly pursuits, including basic and translational science, medical education, health equities research, and the promotion of diversity, equity, and inclusion.
One fellow per year will be accepted into the Yale HFFTP as part of a class of 10 medical oncology-hematology fellows.
- All applications for the 2022 Yale HFFTP are electronically processed through the ERAS (Electronic Residency Application Service) website. Applicants interested in the HFFTP should click on the hematology track in ERAS. Applicants interested either in the HFFTP or in traditional combined medical oncology-hematology training should click on both tracks in ERAS.
We aim to train fellows from diverse backgrounds who will redefine the scope, breadth, and reach of academic hematology, specifically in classical hematology, with the goal of advancing scientific discovery, growing and diversifying the workforce, and improving health equities and access to care for patients with classical hematologic diseases.